5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
Key Takeaways
Adherence to oral antineoplastic therapy commonly falls below 80% and both under-adherence and over-adherence cause harm, so adherence must be measured at every visit rather than assumed.
Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort can reduce plasma concentrations of many oral kinase inhibitors enough to cause treatment failure.
Proton pump inhibitors and H2 blockers substantially reduce absorption of pH-dependent agents such as erlotinib, dasatinib, and pazopanib, so acid suppression must be reviewed before starting these drugs.
Food effects differ by agent: abiraterone must be taken on an empty stomach because food dramatically increases exposure, while capecitabine is taken within 30 minutes after a meal.
Oral antineoplastics are hazardous drugs under USP <800>, so patients and caregivers require instruction on handling, storage, spill management, and disposal at home.
5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
Blueprint focus: ONCC Domain II.B — systemic therapy. Oral agents are systemic therapy delivered without a nurse present. That single fact changes everything about safety, and the exam tests it through adherence, drug interaction, food effect, and home-handling stems.
Why Oral Therapy Is Not Simply More Convenient
An infusion is witnessed, dose-verified, and administered by a nurse who can stop it. An oral kinase inhibitor is taken by a patient who may forget doses, double up after missing one, take it with grapefruit juice, add an over-the-counter omeprazole, or stop it entirely because of a rash they were too embarrassed to report. Every safeguard that the infusion suite provides has to be rebuilt through education, monitoring, and follow-up.
Adherence
Adherence to oral anticancer therapy is frequently reported below 80%, and it declines as therapy lengthens. Both directions are dangerous.
- Under-adherence causes subtherapeutic exposure and treatment failure. In chronic myeloid leukemia, adherence below 90% is associated with markedly lower rates of major molecular response — one of the clearest dose-response relationships in oncology.
- Over-adherence — taking a missed dose late, doubling up, or continuing through a toxicity that should have triggered a hold — causes avoidable grade 3 and 4 events.
Root causes and matched interventions
| Barrier | What it looks like | Intervention |
|---|---|---|
| Financial toxicity | Delayed refills, pill splitting, "I'm stretching it out" | Financial navigator, manufacturer patient assistance program, copay foundation grant, specialty pharmacy benefits check before the first fill |
| Unmanaged toxicity | Silent self-discontinuation after diarrhea or rash | Proactive prophylaxis, scheduled early check-in calls, explicit permission to call |
| Complexity | Multiple agents, cycled on-off schedules, food restrictions | Written calendar, pill organizer, alarms, simplified regimen where possible |
| Cognitive or sensory limits | Missed doses, confusion about the schedule | Caregiver involvement, large-print instructions, teach-back at every visit |
| Beliefs | "I feel fine so I stopped," or fear of dependence | Explain the mechanism and what happens if levels drop |
| Asymptomatic disease | Adjuvant endocrine therapy abandoned in year 2 | Frame absolute benefit; treat side effects rather than accepting discontinuation |
Measure adherence, do not ask a yes-or-no question. Use a normalizing, open prompt — "Most people miss doses sometimes. In the last week, how many did you miss?" — plus pill counts, refill records from the specialty pharmacy, and where available a validated instrument.
Drug and Food Interactions That Change Outcomes
CYP3A4
Most oral kinase inhibitors are CYP3A4 substrates.
- Strong inducers — rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's wort, enzalutamide — lower drug concentrations enough to cause treatment failure. Induction takes days to develop and days to reverse after stopping.
- Strong inhibitors — ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, and grapefruit and Seville orange juice — raise concentrations and cause toxicity.
Whenever a strong interacting drug is unavoidable, either the antineoplastic dose is adjusted according to labeling or a non-interacting alternative is substituted. Antifungal prophylaxis is a common real-world trigger for this problem.
Gastric pH
Several oral agents require an acidic stomach to dissolve. Proton pump inhibitors and H2 receptor antagonists can lower exposure substantially and cause failure.
- Markedly affected: erlotinib, dasatinib, pazopanib, nilotinib, gefitinib, capecitabine (with PPI, an association with worse outcomes has been reported).
- Mitigation: avoid PPIs where possible; if an H2 blocker is required, separate dosing by the interval specified in the label; antacids can often be separated by a few hours.
Food
| Agent | Requirement | Reason |
|---|---|---|
| Abiraterone acetate | Empty stomach — 1 hour before or 2 hours after food | Food can raise exposure severalfold, causing toxicity |
| Capecitabine | Within 30 minutes after a meal | Labeling and trial dosing were established with food |
| Erlotinib | 1 hour before or 2 hours after food | Food increases bioavailability substantially |
| Nilotinib | Avoid food 2 hours before and 1 hour after | Food raises exposure and QT risk |
| Lapatinib | Empty stomach | Food markedly raises exposure |
| All CYP3A4 substrates | Avoid grapefruit and Seville orange | Irreversible intestinal CYP3A4 inhibition |
QT prolongation
Nilotinib, vandetanib, and several other oral agents prolong the QT interval. Obtain a baseline electrocardiogram, correct potassium and magnesium, and review the full medication list for additive QT-prolonging drugs including ondansetron, methadone, azoles, and fluoroquinolones.
Safe Handling at Home
Oral antineoplastics remain hazardous drugs under USP <800> even outside the pharmacy. Teach patients and caregivers:
- Do not crush, split, chew, or open capsules unless the label explicitly permits it.
- Anyone other than the patient handling the tablets should wear disposable gloves.
- Wash hands before and after every dose.
- Store in the original labeled container, out of reach of children and pets, away from heat and humidity; do not put tablets in a shared weekly pill organizer unless a pharmacist confirms it is acceptable.
- People who are pregnant or breastfeeding should not handle the drug.
- Do not flush unused drug or put it in household trash — return it to a take-back program or the dispensing pharmacy.
- For a spill, use gloves, contain and clean with disposable materials, and dispose of them in a sealed bag.
- Body fluids may contain drug for several days after a dose; teach closing the toilet lid and flushing twice, and washing soiled linens separately.
Monitoring Cadence
Build the schedule around the specific agent's toxicity signature. A representative structure:
- Before the first dose: confirm indication and biomarker, reconcile all medications and supplements, check baseline organ function and electrocardiogram if indicated, verify insurance and out-of-pocket cost, and provide written and teach-back education.
- Days 7 to 14: telephone check-in for tolerability and early toxicity — this is when most patients silently stop.
- Every 2 to 4 weeks initially: targeted laboratory studies and toxicity grading (blood pressure and urine protein for VEGF inhibitors; thyroid function for several multikinase inhibitors; liver enzymes for many; complete blood count for PARP inhibitors; glucose and lipids for PI3K and mTOR inhibitors).
- Ongoing: adherence measurement at every visit, re-reconciliation of medications at every visit, and dose modification per label rather than patient-initiated interruption.
Toxicity is a reason to hold and dose-reduce, not a reason for the patient to quit. Say that sentence out loud to every patient starting an oral agent.
A patient with metastatic renal cell carcinoma has been taking pazopanib for 3 months with stable disease. She is started on omeprazole 40 mg daily by her primary care provider for reflux. What is the most important consequence the nurse practitioner should recognize?
Omeprazole will raise pazopanib concentrations and cause severe hepatotoxicity
Omeprazole raises gastric pH and can substantially reduce pazopanib absorption, risking loss of disease control
Omeprazole and pazopanib have no clinically meaningful interaction
Omeprazole will prolong the QT interval additively with pazopanib and requires immediate cardiology referral
A patient starting abiraterone acetate asks how to take it. Which instruction is correct?
Take it with a high-fat breakfast to improve absorption
Take it with grapefruit juice to enhance bioavailability and reduce cost
Take it within 30 minutes after a meal, like capecitabine
Take it on an empty stomach, at least 1 hour before or 2 hours after food, because food substantially increases drug exposure
A patient on imatinib for chronic myeloid leukemia reports at a routine visit that he 'sometimes' misses doses. What is the most appropriate assessment approach by the nurse practitioner?
Ask a yes-or-no question about whether he is taking the medication as prescribed and document his answer
Use a normalizing open-ended prompt about how many doses were missed in the last week, corroborate with pill counts and specialty pharmacy refill records, and explore the specific barrier
Advise him to double the next dose whenever he misses one, to maintain average exposure
Discontinue imatinib and switch to an intravenous regimen, since oral adherence cannot be verified
Sections you finish are checked off in the contents.